Abstract: Catadegbrutinib (BGB-16673) is an orally administered, first-in-class proteolysis-targeting chimera (PROTAC) designed to degrade Bruton's tyrosine kinase (BTK). While covalent and non-covalent BTK inhibitors have transformed the treatment landscape for B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), acquired resistance mutations frequently limit their long-term efficacy. BGB-16673 addresses this unmet clinical need by utilizing an event-driven pharmacological mechanism to ubiquitinate and degrade both wild-type and mutant BTK proteins via the proteasome. Currently under investigation in Phase 1/2 clinical trials (such as CaDAnCe-101) for various relapsed/refractory B-cell malignancies including MCL, BGB-16673 has demonstrated a favorable safety profile and robust clinical efficacy. This review synthesizes the pharmacological properties, molecular mechanisms, current limitations, and future therapeutic perspectives of BGB-16673, with a focus on its application in MCL and related B-cell disorders.
1. Introduction
The treatment of B-cell malignancies, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), relies heavily on the inhibition of the B-cell receptor (BCR) signaling pathway. Bruton's tyrosine kinase (BTK) is a critical cytoplasmic enzyme in this pathway, promoting malignant B-cell activation, proliferation, and survival [1]. The advent of covalent BTK inhibitors (cBTKis) like ibrutinib and zanubrutinib, as well as non-covalent BTK inhibitors (ncBTKis) like pirtobrutinib, has significantly improved patient outcomes. However, patients frequently develop resistance to these therapies, most notably through acquired mutations at the drug-binding site (e.g., C481S) or kinase-impaired mutations (e.g., L528W) [1] [3]. For patients who become refractory to both BTK inhibitors and BCL2 inhibitors, the prognosis is exceptionally poor, highlighting a severe unmet clinical need [1]. To overcome these resistance mechanisms, BTK protein degraders have emerged as a novel therapeutic class. Catadegbrutinib (BGB-16673) is a pioneering PROTAC molecule currently in clinical development for relapsed or refractory B-cell malignancies, including MCL, offering a new paradigm by completely removing the BTK protein rather than merely inhibiting its enzymatic activity [1] [2].
2. Pharmacological Activity
BGB-16673 is an orally administered small molecule that exhibits potent pharmacological activity against B-cell malignancies. Pharmacokinetic studies in animal models demonstrate an elimination half-life ranging from 7.2 to 10 hours, and the compound is highly protein-bound [1]. Pharmacodynamic data from early clinical trials reveal a rapid, substantial, and sustained reduction in BTK protein levels in both peripheral blood and tumor tissue, even at the lowest evaluated dose of 50 mg [1].
In the ongoing Phase 1/2 CaDAnCe-101 dose-escalation and expansion study (NCT05006716), BGB-16673 is being evaluated in patients with relapsed/refractory B-cell malignancies, explicitly including MCL, CLL/SLL, Waldenstrom's macroglobulinemia (WM), and diffuse large B-cell lymphoma (DLBCL) [1]. Clinical efficacy has been highly encouraging; for instance, the overall response rate (ORR) reached 90% in patients with relapsed/refractory WM and 78% in heavily pretreated CLL/SLL patients [2]. The safety profile of BGB-16673 is comparable to other agents in its class, with the most frequently reported adverse events being fatigue, contusion, anemia, diarrhea, and neutropenia. Notably, no instances of atrial fibrillation or hypertension—common adverse events associated with traditional BTK inhibitors—have been reported to date [1].
3. Molecular Mechanism of Action
BGB-16673 operates via an "event-driven" pharmacological mechanism, which distinguishes it from traditional "occupancy-driven" enzyme inhibitors. As a heterobifunctional PROTAC, BGB-16673 consists of a BTK-binding moiety linked to an E3 ubiquitin ligase-binding moiety [1] [3]. The molecule binds simultaneously to the target BTK protein and the cereblon E3 ligase, forming a ternary complex. This proximity catalyzes the polyubiquitination of BTK, tagging it for subsequent degradation by the cellular proteasome [1].
Because PROTACs act catalytically, a single BGB-16673 molecule can induce the degradation of multiple BTK proteins. Once a BTK molecule is degraded, the PROTAC is recycled to target another BTK protein. This mechanism completely removes all BTK activity, including its structural scaffolding functions, leading to a rapid and robust inhibition of downstream BCR signaling cascades and preventing compensatory feedback activation [1].
4. Structure-Activity Relationship (SAR)
The structural design of BGB-16673 allows it to overcome the limitations of traditional BTK inhibitors. By utilizing a bifunctional structure that recruits E3 ligase, BGB-16673 does not rely solely on sustained binding to the BTK active site to exert its effect. Consequently, it is capable of degrading both wild-type (WT) BTK and various mutant forms of BTK that confer resistance to covalent and non-covalent inhibitors [1] [3]. Pre-clinical data indicate that BGB-16673 exhibits a longer duration of response compared to inhibitors like ibrutinib and pirtobrutinib. This suggests a disconnect between the pharmacokinetics and pharmacodynamics of the molecule, meaning BGB-16673 can provide a lasting therapeutic effect even after the drug has been eliminated from the circulation, due to the complete degradation of the target protein [1].
5. Current Limitations
Despite its promising efficacy, BGB-16673 faces several clinical and pharmacological limitations. First, resistance mechanisms to BTK degraders are already beginning to emerge. A recent clinical case report identified the acquisition of a novel BTK mutation, A428D, in a patient whose disease progressed while receiving BGB-16673. This mutation is hypothesized to be kinase-impaired, and it suggests that BTK degrader activity remains vulnerable to selective mutational pressure [1] [3].
Pharmacologically, BGB-16673 is metabolized by the Cytochrome P450 3A (CYP3A) enzyme system, meaning that concurrent use of CYP3A inhibitors or inducers can significantly affect drug exposure. Furthermore, the compound exhibits pH-dependent solubility, necessitating careful consideration of drug-drug interactions with pH-lowering medications (such as proton pump inhibitors) [1]. Finally, while the short-term safety profile is favorable, longer-term follow-up is required to fully assess the potential for treatment-emergent adverse events that may only appear with prolonged exposure [1].
6. Future Perspectives
The future development of BGB-16673 in MCL and other B-cell malignancies will likely focus on combination strategies and optimal therapeutic sequencing. Because B-cell malignancies can develop resistance through multiple pathways, targeting BTK simultaneously via degradation alongside other mechanisms may offer synergistic antitumor activity. A Phase 1b/2 trial (NCT06634589) is currently underway to evaluate BGB-16673 in combination with other targeted agents, including the BCL2 inhibitor sonrotoclax and the covalent BTK inhibitor zanubrutinib, across a range of B-cell malignancies including MCL [1]. Establishing the optimal sequencing of BGB-16673 relative to cellular therapies (such as CAR T-cells) and other targeted agents will be a critical area of ongoing research to maximize durable clinical benefits for patients with multiply relapsed or refractory disease [1].
